CPT® Code 87798

Quick Reference: CPT 87798

• Definition: Code for detecting an infectious agent's DNA or RNA via an amplified probe (PCR) technique when no organism-specific CPT code exists. Bill one unit per distinct organism target.
• Method: Qualitative nucleic acid amplification (for example PCR) intended to answer "detected vs not detected". For quantitation (viral load) without a specific quantitative code, use 87799.
• Panel rule: If a single assay detects multiple organisms, report a multiplex code (typically 87801 or a dedicated panel code) rather than unbundling into multiple 87798 units.
• Hierarchy: Use the most specific organism code available; 87798 is a "not otherwise specified" option and is inappropriate when a dedicated code exists.
• Utilization edits: Medicare's MUE is commonly referenced as 13 units per patient per day, and commercial payers may apply same-day bundling or panel substitution edits.

CPT 87798 is a molecular microbiology billing code used for qualitative infectious agent detection by amplified nucleic-acid methods (most often PCR). It is a general code: the CPT descriptor does not name the organism, and payment integrity therefore depends on documentation that identifies the target(s) and the clinical rationale. This guide focuses on practical 2026 billing behavior: how to decide when 87798 is correct, how to avoid multiplex unbundling denials, how to use modifiers when multiple tests occur on one date, and how to support medical necessity in a way that is review-ready.

Across payers, two patterns account for most 87798 denials. The first is incorrect specificity: billing 87798 for an organism that has a dedicated amplified-probe CPT code. The second is panel unbundling: billing many "each organism" units when the laboratory actually used a multiplex panel. Both issues are correctable by treating coding as a reflection of the assay format rather than the number of results reported.

When in doubt, align the claim to how the instrument ran: singleplex assays support 87798 units; multiplex cartridges support 87801. Clear target naming and indication coding prevent recoupments during post-payment review.

1. Test Method & Proper Usage Criteria

87798 represents an amplified nucleic-acid test for an infectious agent, reported per organism. Operationally, that means the unit count should match the number of discrete organism targets tested by discrete assays, not the number of organism results a panel instrument prints. The code is used for qualitative detection; it is not intended to represent quantitative copy-number reporting. If the laboratory is measuring viral load and there is no organism-specific quantitative code, CPT 87799 is the "NOS" quantitative alternative. When a dedicated viral load code exists, use the dedicated code instead of 87799.

Most-specific-code rule

The first coding checkpoint is specificity. If a dedicated amplified-probe code exists for the organism, that code takes precedence and should replace 87798. Payer policies that address nucleic acid probe testing reinforce this hierarchy and commonly deny claims that use generic codes when specific codes are available. Because CPT updates over time, many laboratories maintain an internal crosswalk linking each orderable test to its preferred CPT code and review it at least annually and whenever new codes become effective.

Singleplex testing vs. multiplex testing

Singleplex (single-organism) testing: When the laboratory runs a single target NAAT for one organism, bill 87798 once if no dedicated code exists. If the same patient has separate singleplex assays for two different organisms on the same day and both map to 87798, billing two 87798 lines can be defensible, but it must be supported by a report that lists both targets and by an ordering rationale that explains why both were suspected.

Multiplex (multi-organism) testing: If one assay tests multiple targets in one analytical run, report the appropriate panel code or 87801 rather than multiple 87798 units. Payer guidance has explicitly reminded providers that reimbursement for multiple individual labs may be limited, and consolidation logic may be applied when the billing pattern resembles panel testing. From a compliance perspective, the clean rule is: one multiplex run equals one billed multiplex service, even if the laboratory reports multiple positives and negatives.

A common gray zone is reflex workflows. If a provider orders a targeted test and the laboratory later adds additional discrete assays (not a multiplex panel) based on new clinical information, additional 87798 units may be appropriate. In that setting, documentation must show the sequence: which targets were ordered initially, what new information justified the added target(s), and that the added tests were distinct assays rather than additional panel components.

2. Documentation & Medical Necessity Standards

Because 87798 is organism-agnostic on the claim, documentation is the mechanism that makes the code auditable. Payers reviewing 87798 commonly look for two items: an explicit list of organisms tested and a credible clinical reason each target was tested. Documentation should be sufficient for a reviewer to reconstruct the service without contacting the laboratory.

• Order clarity: The order should name the intended organism (or the clearly named panel) and specify specimen type. Orders that list only billing codes or generic "PCR" language are weak support in audits.
• Test report mapping: The lab report should list the organism target associated with each 87798 unit and the qualitative result. If the claim contains multiple 87798 units, the report should show multiple discrete targets, not a single multiplex output.
• Clinical rationale: Notes should show why molecular testing was necessary (for example immunocompromised host, severe disease, atypical exposure, or need for rapid organism-directed therapy). For policy-sensitive areas such as expanded pathogen panels, payer coverage frameworks emphasize clinical context and panel size.
• Repeat testing rationale: If a test is repeated the same day, record why the repeat was clinically needed (new specimen, confirmation, indeterminate first result). Repeats due to internal laboratory error are not billable clinical repeats.

In practice, the most defensible 87798 claims are those where the organism is clearly named in the order and report, and the diagnosis and clinical history make that organism plausible. When broad molecular testing is performed, it is often easier to defend the claim by using the panel code that matches the assay format rather than by attempting to document many 87798 units. When payer policy disputes a panel's medical necessity, strong documentation can still matter for appeals, but correct "panel-format" coding reduces the probability of an initial denial and reduces the number of claims pushed into manual review.

3. Common ICD-10 Codes & Indications

87798 can appear across many infectious syndromes, but reimbursement is often diagnosis-driven. The best practice is to use the most specific ICD-10 code that matches the suspected organism and the clinical syndrome, and to avoid relying only on generic symptom codes when ordering broad testing. Examples that commonly align with molecular testing include:

• A90 -- Dengue fever: Suspected dengue confirmed by qualitative PCR. CMS has issued billing guidance addressing Zika, dengue, and chikungunya PCR testing workflows.
• A92.0 -- Chikungunya virus disease: Similar arboviral PCR scenarios where a dedicated CPT code may not be available and documentation of travel exposure supports necessity.
• A84.9 -- Viral encephalitis, unspecified: Neurologic syndromes may justify targeted NAATs for uncommon viruses in CSF when rapid identification changes management.
• R50.9 -- Fever, unspecified: Fever of unknown origin can support targeted testing when paired with documentation of risk factors and prior negative evaluations.

Symptom-only codes may be insufficient for expensive panels in some payer policies. For example, policies addressing genitourinary PCR panels frequently tie coverage to explicit criteria rather than to broad symptom codes. When a claim is denied as "not medically necessary," the quickest improvement is often to tighten the ICD-10 selection to reflect the suspected organism or the high-risk clinical state, and to ensure the clinical note documents why molecular testing was expected to change management.

4. Medicare & Payer Billing Guidelines

Payers manage molecular testing using three levers: unit limits (such as MUEs), bundling edits (including panel substitution), and coverage policies (including LCDs). For 87798, these levers interact most strongly when many units are billed on the same date.

Medicare MUE limits: Medicare's MUE value for CPT 87798 is commonly referenced as 13 units per day. Units above the edit are typically denied. While the MUE is not a coverage policy by itself, it is a strong signal that very high unit counts will face scrutiny and that multiplex coding may be more appropriate.

Bundling and multiplex substitution

Commercial payers may apply edits that consolidate multiple single-organism NAAT charges into one multiplex code when the pattern looks like a panel. Provider-facing reminders have explicitly addressed reimbursement limits when multiple individual labs are billed, reinforcing that "one panel, one payment" logic is common. The practical lesson is that claim construction should mirror the assay format; otherwise, the payer will reconstruct it on your behalf, usually by paying one multiplex service and denying the additional units.

Coverage policy context

Coverage policies often distinguish targeted testing from expanded panels and may require documentation of severity, immunocompromise, or a defined clinical scenario. MolDX policy frameworks, for example, discuss molecular pathogen panel testing in ways that are sensitive to panel size and clinical context. If a claim uses many units of 87798, it may be evaluated as an expanded panel regardless of how the laboratory intended to describe it, which increases the importance of the ordering indication, the ICD-10 code selection, and the clinical record supporting why broad testing was reasonable and necessary.

When a denial occurs, the first troubleshooting step is usually to determine whether the payer denied for coding (bundling/unbundling) or for coverage (medical necessity). Coding denials are often corrected by rebilling with 87801 or the appropriate panel CPT. Coverage denials require clinical documentation and, when applicable, alignment with the payer's published criteria.

5. Modifier Usage (59, 91, QW)

Multiple 87798 lines on one date are frequently auto-denied unless modifiers explain why the duplicates are legitimate. Modifier selection should reflect the clinical reality: distinct organism targets versus repeat testing of the same target.

Modifier 59 -- Distinct procedural service

Use modifier 59 when multiple 87798 services on the same date represent distinct assays for distinct targets (or distinct specimen sources) and would otherwise be read as duplicates. In this context, 59 functions as a "different organism/different service" signal. Guidance discussing infectious disease testing emphasizes correct reporting and avoidance of unbundling behavior, which is the same compliance objective addressed by appropriate modifier use.

Modifier 91 -- Repeat clinical diagnostic test

Use modifier 91 when the same assay for the same organism is repeated on the same day to obtain a new clinical result. The repeated test should be medically necessary (new specimen, confirmation, indeterminate first result). Discussions of billing multiple units highlight the need for repeat-test modifiers to avoid duplicate denials. Do not use 91 for different organisms; that is a distinct service, not a repeat.

Modifier QW -- CLIA-waived test

Append QW only when the specific molecular assay performed is CLIA-waived and the billing payer requires QW reporting for waived methodology. Rapid molecular reimbursement summaries emphasize the role of waived status in Medicare billing workflows. Most 87798 testing is not waived; QW is the exception, not the norm.

6. Comparison: 87797 vs 87798 vs 87799 vs 87801

The neighboring codes divide molecular microbiology testing by amplification and by organism count. This table summarizes the practical differences used in claims decisions:

In audits, the key question is whether the laboratory's claim matches the analytical design. If one multiplex assay was used, 87801 (or a dedicated panel CPT) is expected. If discrete assays were used, 87798 can be correct, but the record must show the discrete targets and the rationale for each one.

7. Clinical Scenario Examples

These scenarios demonstrate compliant coding patterns and the documentation elements that support payment.

Scenario 1: Tropical fever -- single pathogen PCR

Patient: Returned traveler with high fever, rash, and thrombocytopenia. Action: Targeted qualitative dengue PCR ordered and performed. Coding: 87798 x1. Why it works: One organism, qualitative method, and CMS guidance addresses arboviral PCR billing workflows.

Scenario 2: GI multiplex panel

Patient: Immunocompromised patient with severe diarrhea. Action: One multiplex GI panel run on stool with multiple targets reported. Coding: 87801 x1 (or a dedicated panel CPT when applicable). Why it works: Matches assay format and aligns with payer consolidation logic for multiple individual labs and policy frameworks that evaluate panel size and context.

Scenario 3: Two discrete targets billed as 87798

Patient: Transplant recipient with fever and an exposure history suggesting two uncommon pathogens. Action: Two separate singleplex qualitative assays performed for two distinct organisms that lack dedicated CPT codes. Coding: 87798 on one line and 87798-59 on the second line. Why it works: Distinct tests are documented and modifier 59 prevents duplicate denial while reflecting separate services.

Scenario 4: Repeat same-day testing

Patient: Hospitalized patient where the initial qualitative PCR is indeterminate due to inhibition. Action: New specimen collected and the same test repeated to obtain a valid result. Coding: 87798 for the first test and 87798-91 for the repeat. Why it works: Modifier 91 indicates a clinically necessary repeat and helps avoid duplicate denial.

Scenario 5: Unbundled genitourinary panel corrected

Patient: Vaginitis symptoms sent for a multiplex genitourinary panel. Problem: Lab bills multiple 87798 units for panel targets; payer denies or consolidates based on panel rules and genitourinary panel policy logic. Fix: Rebill using 87801 (or the appropriate panel CPT) as a single service and ensure the report states the multiplex methodology.

flowchart TD
    A[Molecular test ordered for infectious agent] --> B{Does a dedicated\norganism-specific\nCPT code exist?}
    B -->|Yes| C[Use the dedicated code\ne.g. 87491, 87631]
    B -->|No| D{Is the test\nqualitative or\nquantitative?}
    D -->|Quantitative\nviral load| E[Use 87799\nNOS quantitative]
    D -->|Qualitative\ndetected/not detected| F{Was a singleplex\nor multiplex assay\nperformed?}
    F -->|Singleplex\none organism per assay| G[Bill 87798 x1\nper distinct target]
    F -->|Multiplex\nmultiple organisms per run| H[Bill 87801 or\ndedicated panel CPT]
    G --> I{Multiple 87798\non same date?}
    I -->|Different organisms| J[Add modifier 59\nto additional lines]
    I -->|Same organism repeated| K[Add modifier 91\nto repeat test]
    I -->|Single test only| L[No modifier needed]